Deborah Burke Net Worth

The estimated Net Worth of Deborah Burke is at least 516 千$ dollars as of 15 November 2014. Deborah Burke owns over 6,438 units of Exelixis Inc stock worth over 516,010$ and over the last 10 years Deborah sold EXEL stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Deborah Burke EXEL stock SEC Form 4 insiders trading

Deborah has made over 1 trades of the Exelixis Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Deborah exercised 6,438 units of EXEL stock worth 171,444$ on 15 November 2014.

The largest trade Deborah's ever made was exercising 6,438 units of Exelixis Inc stock on 15 November 2014 worth over 171,444$. On average, Deborah trades about 6,438 units every 0 days since 2014. As of 15 November 2014 Deborah still owns at least 19,377 units of Exelixis Inc stock.

You can see the complete history of Deborah Burke stock trades at the bottom of the page.

What's Deborah Burke's mailing address?

Deborah's mailing address filed with the SEC is C/O EXELIXIS, INC., 210 E. GRAND AVE., SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Exelixis Inc

Over the last 23 years, insiders at Exelixis Inc have traded over 82,392,913$ worth of Exelixis Inc stock and bought 1,847,609 units worth 19,175,184$ . The most active insiders traders include Jean Francois Formela、Michael Morrissey、Stelios Papadopoulos. On average, Exelixis Inc executives and independent directors trade stock every 12 days with the average trade being worth of 898,709$. The most recent stock trade was executed by Jeffrey Hessekiel on 26 August 2024, trading 20,000 units of EXEL stock currently worth 488,200$.

What does Exelixis Inc do?

exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.

Complete history of Deborah Burke stock trades at Exelixis Inc

Exelixis Inc executives and stock owners

Exelixis Inc executives and other stock owners filed with the SEC include:

• Dr. Michael M. Morrissey,
  CEO, Pres & Director
• Michael Morrissey,
  President, Chief Executive Officer, Director
• Gisela Schwab,
  President - Product Development and Medical Affairs, Chief Medical Officer
• Christopher J. Senner,
  Exec. VP & CFO
• Christopher Senner,
  Chief Financial Officer, Executive Vice President
• Jeffrey J. Hessekiel,
  Exec. VP, Gen. Counsel & Sec.
• Jeffrey Hessekiel,
  Executive Vice President, General Counsel
• Patrick J. Haley M.B.A., MBA,
  Exec. VP of Commercial
• Peter Lamb,
  Executive Vice President - Scientific Strategy, Chief Scientific Officer
• Stelios Papadopoulos,
  Independent Chairman of the Board, Co-Founder
• Charles Cohen,
  Independent Director
• Jack Wyszomierski,
  Independent Director
• George Poste,
  Independent Director
• Vincent Marchesi,
  Independent Director
• Julie Smith,
  Independent Director
• Alan Garber,
  Independent Director
• Maria Freire,
  Independent Director
• Carl Feldbaum,
  Independent Director
• Lance Willsey,
  Independent Director
• Dr. Stelios Papadopoulos Ph.D.,
  Co-Founder & Independent Chairman
• Patrick Haley,
  Executive Vice President - Commercial
• Laura Dillard,
  Exec. VP of HR
• Gregg Bernier,
  VP of Marketing
• Susan T. Hubbard,
  Exec. VP of Public Affairs & Investor Relations
• Dr. Peter Lamb,
  Exec. VP of Scientific Strategy & Chief Scientific Officer
• Dr. Dana T. Aftab,
  Exec. VP of Bus. Operations
• George A Scangos,
  Director
• Dana Aftab,
  CSO/EVP Disc & Trans Research
• Mary C Beckerle,
  Director
• David Edward Caligan Partne...,
  
• Sue Gail Eckhardt,
  Director
• Bob Oliver,
  Director
• Tomas J. Heyman,
  Director
• Jacqueline Wright,
  Director
• Pamela A Simonton,
  VP, Corp Tech Development
• Frank Karbe,
  Senior VP & CFO
• Deborah Burke,
  SVP & Chief Financial Officer
• Jeffrey Latts,
  Sr VP, Chief Medical Officer
• Peter Stalder,
  Director
• Jason S Fisherman,
  Director
• Kristine M Ball,
  Controller & Interim CFO
• Frank Mccormick,
  Director
• Steven P James,
  Sr VP, Commercial Ops
• Jane M Green,
  VP, Corp Communications
• Glen Y Sato,
  CFO Sec and General Counsel
• Jean Francois Formela,
  Director
• Lupe M Rivera,
  VP, HUMAN RESOURCES
• Frances K Heller,
  EVP, Business Development
• Ian D Malcolm,
  VP, STRATEGIC MARKETING
• Christoph Pereira,
  VP, Legal Affairs & Secretary
• J. Scott Garland,
  EVP & Chief Commerical Officer
• Gregory Plowman,
  Sr VP, Research
• Geoffrey M Duyk,
  Pres R&D & Chief Sc Off
• Vicki L Goodman,
  EVP, Prod Dev & Med Aff &CMO
• Amy C. Peterson,
  EVP Prod Dev & Med Aff & CMO